Skip to main content
In stock | Targeted Therapy (Investigational Antibody / ADC)

Petosemtamab

Oncology Type Solid Tumour
Drug Class / Mechanism Investigational Monoclonal / ADC Agent
No Image
Description

Petosemtamab is classified as an Investigational Monoclonal / ADC Agent, sourced for use within our Targeted Therapy (Investigational Antibody / ADC) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Investigational Antibody / ADC)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3